Continuous intravenous tirofiban can improve the 90-day functional outcome and decrease 90-day mortality without increasing bleeding risk in acute ischemic stroke patients treated by endovascular therapy: A meta-analysis

替罗非班 医学 改良兰金量表 优势比 随机对照试验 内科学 冲程(发动机) 脑出血 麻醉 外科 蛛网膜下腔出血 缺血 缺血性中风 心肌梗塞 经皮冠状动脉介入治疗 工程类 机械工程
作者
Aiwu Zhang,Nihong Wu,Xintong Liu,Tao Jiang
出处
期刊:Journal of Clinical Neuroscience [Elsevier]
卷期号:99: 109-116 被引量:7
标识
DOI:10.1016/j.jocn.2022.03.008
摘要

Background The role of continuous intravenous administration of tirofiban in endovascular therapy is still unclear. This meta-analysis aims to evaluate the 90-day functional prognosis in acute ischemic stroke patients (AIS) treated by endovascular treatment and intravenous administration of tirofiban. Methods We searched PubMed, Embase, and CENTRAL databases with the subject terms “tirofiban”, “brain ischemia”, and some related free words. Inclusion criteria were: (1) cohort study or randomized control trials; (2) AIS patients who received endovascular therapy; (3) the intervention or exposure was intravenous tirofiban monotherapy or combined with intra-arterial tirofiban; (4) containing data on modified Rankin Scale at 90 days and including at least one of the following indicators: mortality, symptomatic intracranial hemorrhage (sICH), intracranial hemorrhage (ICH), and recanalization. A summary odds ratio was calculated. Results Twelve eligible studies, consisting of 3268 AIS participants, were identified. There was a significant trend of favorable outcomes (measured by mRS at three months) in the tirofiban group (ORs = 1.36; 95% CI = 1.09–1.70). In addition, compared with the non-tirofiban group, intravenous tirofiban was significantly associated with decreased risk of 90-day mortality (ORs = 0.73; 95% CI:0.59–0.89) and increased recanalization rate (ORs = 1.50; 95% CI:1.08–2.09) but no significant difference in rates of sICH (ORs = 0.93; 95% CI = 0.70–1.24) or ICH (ORs = 0.84; 95% CI = 0.62–1.15). Conclusions Intravenous tirofiban appears to be safe and effective when used following intra-arterial tirofiban or as monotherapy in AIS patients treated by endovascular therapy, which can improve the 90-day functional outcome, decrease the 90-day mortality and increase the possibility of early recanalization without increasing rates of sICH and ICH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冷静的缘分完成签到 ,获得积分10
1秒前
vision完成签到,获得积分10
1秒前
wanci应助文艺鞋垫采纳,获得10
2秒前
3秒前
kingebo完成签到,获得积分10
3秒前
vision发布了新的文献求助10
4秒前
zhang值完成签到,获得积分10
5秒前
5秒前
7秒前
7秒前
7秒前
7秒前
丙子哥完成签到,获得积分10
8秒前
8秒前
木木发布了新的文献求助10
9秒前
xwwwww发布了新的文献求助10
9秒前
乌龟娟完成签到,获得积分10
10秒前
10秒前
blueming完成签到,获得积分10
10秒前
11秒前
11秒前
shizi完成签到,获得积分10
11秒前
11秒前
lalala发布了新的文献求助10
12秒前
天天快乐应助欧耶采纳,获得10
13秒前
CHH发布了新的文献求助10
13秒前
叶落孤城发布了新的文献求助10
13秒前
顾矜应助珂伟采纳,获得10
14秒前
14秒前
wanli完成签到,获得积分10
15秒前
可靠之玉完成签到,获得积分10
15秒前
zhao发布了新的文献求助10
15秒前
椒盐丸子发布了新的文献求助10
16秒前
尹冰露发布了新的文献求助10
16秒前
情怀应助kk采纳,获得10
16秒前
andy_lee发布了新的文献求助10
17秒前
17秒前
Nature发布了新的文献求助10
17秒前
王婷完成签到,获得积分10
18秒前
y2ktwo完成签到,获得积分20
20秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Mission to Mao: Us Intelligence and the Chinese Communists in World War II 600
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3304869
求助须知:如何正确求助?哪些是违规求助? 2938862
关于积分的说明 8490317
捐赠科研通 2613294
什么是DOI,文献DOI怎么找? 1427368
科研通“疑难数据库(出版商)”最低求助积分说明 662925
邀请新用户注册赠送积分活动 647561